CD19 and precursor B-cell acute lymphoblastic leukemia: Five CD19 CAR T products have received Food and Drug Administration (FDA) approval, demonstrating CR rates of 60%–93% in B-ALL and 40%–50% in DLBCL, whereas in patients with chronic lymphocytic leukemia (CLL), CR rates of 15%–30% have been observed.6